The field of rare cancer research is rapidly transforming, marked by significant progress in clinical trials and treatment strategies. Rare cancers, as defined by the National Cancer Institute, occur in fewer than 150 cases per million people each year, …
PURPOSEOxaliplatin-based adjuvant chemotherapy is used for stage III colon cancer, but may induce disabling neurotoxicity. We previously showed that the incidence of oxaliplatin-induced peripheral neurotoxicity…
PURPOSEAndrogen receptor signaling inhibitors (ARSIs) are mainstay treatments for metastatic prostate cancer. Hyperglycemia is a common side effect, but limited data exist on outcomes such…
In 2025, ASCO published a guideline update on the use of sentinel lymph node biopsy (SLNB) in patients with early-stage breast cancer (stages I and…
PURPOSEMany cancer survivors have high levels of distress and psychosocial symptoms. Two mind-body interventions for treating these problems are Mindfulness-Based Cancer Recovery (MBCR) and Tai…
PURPOSETo examine trends over time in clinical trial diversity for oncology therapeutics, identify bright spot trials adequately representing Black or Latino patients, and examine their…
In 2025, ASCO published a guideline update on the use of sentinel lymph node biopsy (SLNB) in patients with early-stage breast cancer (stages I and…
Resection of liver metastases is considered the only treatment with curative potential for patients with metastatic colorectal cancer to the liver (CRLM). However, only a…
PURPOSEThe development of targeted therapeutics has revolutionized treatment for elderly patients with AML. Two doublet regimens are approved in the frontline setting for intensive chemotherapy…
PURPOSETo assess the impact and outcomes of a novel program for routine preemptive DPYD testing in fluoropyrimidine (FP)-naïve patients.PATIENTS AND METHODSThis single-center, retrospective cohort study…
PURPOSEThe development of targeted therapeutics has revolutionized treatment for elderly patients with AML. Two doublet regimens are approved in the frontline setting for intensive chemotherapy…
